The Role of Cathelicidin LL-37 in Cancer Development

Overview

Journal Arch Immunol Ther Exp (Warsz)

Publisher Sciendo

Specialty Allergy & Immunology

Date 2015 Sep 24

PMID 26395996

Citations 49

Authors

Ewelina Piktel

Katarzyna Niemirowicz

Urszula Wnorowska

Marzena Watek

Tomasz Wollny

Katarzyna Gluszek

Stanislaw Gozdz

Ilya Levental

Robert Bucki

Affiliations

Soon will be listed here.

Abstract

LL-37 is a C-terminal peptide proteolytically released from 18 kDa human cathelicidin protein (hCAP18). Chronic infections, inflammation, tissue injury and tissue regeneration are all linked with neoplastic growth, and involve LL-37 antibacterial and immunomodulatory functions. Such a link points to the possible involvement of LL-37 peptide in carcinogenesis. An increasing amount of evidence suggests that LL-37 can have two different and contradictory effects--promotion or inhibition of tumor growth. The mechanisms are tissue-specific, complex, and depend mostly on the ability of LL-37 to act as a ligand for different membrane receptors whose expression varies on different cancer cells. Overexpression of LL-37 was found to promote development and progression of ovarian, lung and breast cancers, and to suppress tumorigenesis in colon and gastric cancer. This review explores and summarizes the current views on how LL-37 contributes to immunity, pathophysiology and cell signaling involved in malignant tumor growth.

Citing Articles

Cathelicidins: Opportunities and Challenges in Skin Therapeutics and Clinical Translation.

Dzurova L, Holaskova E, Pospisilova H, Schneider Rauber G, Frebortova J Antibiotics (Basel). 2025; 14(1).

PMID: 39858288 PMC: 11762488. DOI: 10.3390/antibiotics14010001.

Glioblastoma Multiforme: Sensitivity to Antimicrobial Peptides LL-37 and PG-1, and Their Combination with Chemotherapy for Predicting the Overall Survival of Patients.

Chernov A, Skliar S, Kim A, Tsapieva A, Pyurveev S, Filatenkova T Pharmaceutics. 2024; 16(9).

PMID: 39339270 PMC: 11435188. DOI: 10.3390/pharmaceutics16091234.

Antimicrobial peptide-based strategies to overcome antimicrobial resistance.

Girdhar M, Sen A, Nigam A, Oswalia J, Kumar S, Gupta R Arch Microbiol. 2024; 206(10):411.

PMID: 39311963 DOI: 10.1007/s00203-024-04133-x.

Lung antimicrobial proteins and peptides: from host defense to therapeutic strategies.

Di Y, Kuhn J, Mangoni M Physiol Rev. 2024; 104(4):1643-1677.

PMID: 39052018 PMC: 11495187. DOI: 10.1152/physrev.00039.2023.

Host defense peptides human β defensin 2 and LL-37 ameliorate murine necrotizing enterocolitis.

Lueschow-Guijosa S, Stanford A, Berger J, Gong H, Boly T, Jensen B iScience. 2024; 27(6):109993.

PMID: 38846005 PMC: 11154634. DOI: 10.1016/j.isci.2024.109993.

References

Kretowski R, Stypulkowska A, Cechowska-Pasko M . Efficient apoptosis and necrosis induction by proteasome inhibitor: bortezomib in the DLD-1 human colon cancer cell line. Mol Cell Biochem. 2014; 398(1-2):165-73. PMC: 4229651. DOI: 10.1007/s11010-014-2216-y. View

Yousif N, Al-Amran F, Hadi N, Lee J, Adrienne J . Expression of IL-32 modulates NF-κB and p38 MAP kinase pathways in human esophageal cancer. Cytokine. 2012; 61(1):223-7. DOI: 10.1016/j.cyto.2012.09.022. View

Currie S, Gwyer Findlay E, McHugh B, Mackellar A, Man T, Macmillan D . The human cathelicidin LL-37 has antiviral activity against respiratory syncytial virus. PLoS One. 2013; 8(8):e73659. PMC: 3758310. DOI: 10.1371/journal.pone.0073659. View

Koczulla R, von Degenfeld G, Kupatt C, Krotz F, Zahler S, Gloe T . An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J Clin Invest. 2003; 111(11):1665-72. PMC: 156109. DOI: 10.1172/JCI17545. View

Sorensen O, Follin P, Johnsen A, Calafat J, Tjabringa G, Hiemstra P . Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. Blood. 2001; 97(12):3951-9. DOI: 10.1182/blood.v97.12.3951. View

Heilborn J, Nilsson M, Chamorro Jimenez C, Sandstedt B, Borregaard N, Tham E . Antimicrobial protein hCAP18/LL-37 is highly expressed in breast cancer and is a putative growth factor for epithelial cells. Int J Cancer. 2004; 114(5):713-9. DOI: 10.1002/ijc.20795. View

von Haussen J, Koczulla R, Shaykhiev R, Herr C, Pinkenburg O, Reimer D . The host defence peptide LL-37/hCAP-18 is a growth factor for lung cancer cells. Lung Cancer. 2007; 59(1):12-23. DOI: 10.1016/j.lungcan.2007.07.014. View

Kuroda K, Fukuda T, Yoneyama H, Katayama M, Isogai H, Okumura K . Anti-proliferative effect of an analogue of the LL-37 peptide in the colon cancer derived cell line HCT116 p53+/+ and p53-/-. Oncol Rep. 2012; 28(3):829-34. DOI: 10.3892/or.2012.1876. View

Nold-Petry C, Rudloff I, Baumer Y, Ruvo M, Marasco D, Botti P . IL-32 promotes angiogenesis. J Immunol. 2013; 192(2):589-602. PMC: 4007307. DOI: 10.4049/jimmunol.1202802. View

10.

Richardson P, Mitsiades C, Hideshima T, Anderson K . Proteasome inhibition in the treatment of cancer. Cell Cycle. 2005; 4(2):290-6. View

11.

Gao P, Zhao H, You J, Jing F, Hu Y . Association between interleukin-8 -251A/T polymorphism and risk of lung cancer: a meta-analysis. Cancer Invest. 2014; 32(10):518-25. DOI: 10.3109/07357907.2014.964410. View

12.

Levine B, Abrams J . p53: The Janus of autophagy?. Nat Cell Biol. 2008; 10(6):637-9. PMC: 2739720. DOI: 10.1038/ncb0608-637. View

13.

McSorley M, Alberg A, Allen D, Allen N, Brinton L, Dorgan J . C-reactive protein concentrations and subsequent ovarian cancer risk. Obstet Gynecol. 2007; 109(4):933-41. DOI: 10.1097/01.AOG.0000257126.68803.03. View

14.

Kim J, Kim H, Choi J, Lee K, Kim T, Cho B . The antimicrobial peptide human cationic antimicrobial protein-18/cathelicidin LL-37 as a putative growth factor for malignant melanoma. Br J Dermatol. 2010; 163(5):959-67. DOI: 10.1111/j.1365-2133.2010.09957.x. View

15.

Galluzzi L, Joza N, Tasdemir E, Maiuri M, Hengartner M, Abrams J . No death without life: vital functions of apoptotic effectors. Cell Death Differ. 2008; 15(7):1113-23. PMC: 2917777. DOI: 10.1038/cdd.2008.28. View

16.

Byfield F, Kowalski M, Cruz K, Leszczynska K, Namiot A, Savage P . Cathelicidin LL-37 increases lung epithelial cell stiffness, decreases transepithelial permeability, and prevents epithelial invasion by Pseudomonas aeruginosa. J Immunol. 2011; 187(12):6402-9. DOI: 10.4049/jimmunol.1102185. View

17.

Arnoult D, Gaume B, Karbowski M, Sharpe J, Cecconi F, Youle R . Mitochondrial release of AIF and EndoG requires caspase activation downstream of Bax/Bak-mediated permeabilization. EMBO J. 2003; 22(17):4385-99. PMC: 202365. DOI: 10.1093/emboj/cdg423. View

18.

Ferrari D, Pizzirani C, Adinolfi E, Lemoli R, Curti A, Idzko M . The P2X7 receptor: a key player in IL-1 processing and release. J Immunol. 2006; 176(7):3877-83. DOI: 10.4049/jimmunol.176.7.3877. View

19.

Barlow P, Svoboda P, Mackellar A, Nash A, York I, Pohl J . Antiviral activity and increased host defense against influenza infection elicited by the human cathelicidin LL-37. PLoS One. 2011; 6(10):e25333. PMC: 3198734. DOI: 10.1371/journal.pone.0025333. View

20.

Mai C, Kang Y, Pichika M . Should a Toll-like receptor 4 (TLR-4) agonist or antagonist be designed to treat cancer? TLR-4: its expression and effects in the ten most common cancers. Onco Targets Ther. 2013; 6:1573-87. PMC: 3821792. DOI: 10.2147/OTT.S50838. View